These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24376359)

  • 1. Improved function and proliferation of adult human beta cells engrafted in diabetic immunodeficient NOD-scid IL2rγ(null) mice treated with alogliptin.
    Jurczyk A; Diiorio P; Brostowin D; Leehy L; Yang C; Urano F; Harlan DM; Shultz LD; Greiner DL; Bortell R
    Diabetes Metab Syndr Obes; 2013; 6():493-9. PubMed ID: 24376359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lixisenatide accelerates restoration of normoglycemia and improves human beta-cell function and survival in diabetic immunodeficient NOD-scid IL-2rg(null) RIP-DTR mice engrafted with human islets.
    Yang C; Loehn M; Jurczyk A; Przewozniak N; Leehy L; Herrera PL; Shultz LD; Greiner DL; Harlan DM; Bortell R
    Diabetes Metab Syndr Obes; 2015; 8():387-98. PubMed ID: 26316789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor induces β-cell neogenesis from adult human pancreatic duct cells implanted in immunodeficient mice.
    Suarez-Pinzon WL; Rabinovitch A
    Cell Transplant; 2011; 20(9):1343-9. PubMed ID: 21396168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice.
    Moritoh Y; Takeuchi K; Asakawa T; Kataoka O; Odaka H
    Eur J Pharmacol; 2008 Jul; 588(2-3):325-32. PubMed ID: 18499100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice.
    Moritoh Y; Takeuchi K; Asakawa T; Kataoka O; Odaka H
    Br J Pharmacol; 2009 Jun; 157(3):415-26. PubMed ID: 19371350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucose stimulates human beta cell replication in vivo in islets transplanted into NOD-severe combined immunodeficiency (SCID) mice.
    Levitt HE; Cyphert TJ; Pascoe JL; Hollern DA; Abraham N; Lundell RJ; Rosa T; Romano LC; Zou B; O'Donnell CP; Stewart AF; Garcia-Ocaña A; Alonso LC
    Diabetologia; 2011 Mar; 54(3):572-82. PubMed ID: 20936253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rejection of human islets and human HLA-A2.1 transgenic mouse islets by alloreactive human lymphocytes in immunodeficient NOD-scid and NOD-Rag1(null)Prf1(null) mice.
    Banuelos SJ; Shultz LD; Greiner DL; Burzenski LM; Gott B; Lyons BL; Rossini AA; Appel MC
    Clin Immunol; 2004 Sep; 112(3):273-83. PubMed ID: 15308121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene transfer of constitutively active Akt markedly improves human islet transplant outcomes in diabetic severe combined immunodeficient mice.
    Rao P; Roccisana J; Takane KK; Bottino R; Zhao A; Trucco M; García-Ocaña A
    Diabetes; 2005 Jun; 54(6):1664-75. PubMed ID: 15919787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human immune system development and rejection of human islet allografts in spontaneously diabetic NOD-Rag1null IL2rgammanull Ins2Akita mice.
    Brehm MA; Bortell R; Diiorio P; Leif J; Laning J; Cuthbert A; Yang C; Herlihy M; Burzenski L; Gott B; Foreman O; Powers AC; Greiner DL; Shultz LD
    Diabetes; 2010 Sep; 59(9):2265-70. PubMed ID: 20570944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new immunodeficient hyperglycaemic mouse model based on the Ins2Akita mutation for analyses of human islet and beta stem and progenitor cell function.
    Pearson T; Shultz LD; Lief J; Burzenski L; Gott B; Chase T; Foreman O; Rossini AA; Bottino R; Trucco M; Greiner DL
    Diabetologia; 2008 Aug; 51(8):1449-56. PubMed ID: 18563383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stimulating β-cell replication and improving islet graft function by AR231453, A GPR119 agonist.
    Gao J; Tian L; Weng G; O'Brien TD; Luo J; Guo Z
    Transplant Proc; 2011 Nov; 43(9):3217-20. PubMed ID: 22099761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Encapsulated piscine (tilapia) islets for diabetes therapy: studies in diabetic NOD and NOD-SCID mice.
    Safley SA; Cui H; Cauffiel SM; Xu BY; Wright JR; Weber CJ
    Xenotransplantation; 2014; 21(2):127-39. PubMed ID: 24635017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating insulin secretagogues in a humanized mouse model with functional human islets.
    Luo J; Nguyen K; Chen M; Tran T; Hao J; Tian B; Rulifson IC; Zhang Y; Tian L; Zhang Y; Lopez E; Lin DC; Wang Y; Ma Z; Houze J; Guo Z
    Metabolism; 2013 Jan; 62(1):90-9. PubMed ID: 22982177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with glucagon-like peptide-1 and gastrin induces beta-cell neogenesis from pancreatic duct cells in human islets transplanted in immunodeficient diabetic mice.
    Suarez-Pinzon WL; Lakey JR; Rabinovitch A
    Cell Transplant; 2008; 17(6):631-40. PubMed ID: 18819251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancing pancreatic Beta-cell regeneration in vivo with pioglitazone and alogliptin.
    Yin H; Park SY; Wang XJ; Misawa R; Grossman EJ; Tao J; Zhong R; Witkowski P; Bell GI; Chong AS
    PLoS One; 2013; 8(6):e65777. PubMed ID: 23762423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A nanobody-based nuclear imaging tracer targeting dipeptidyl peptidase 6 to determine the mass of human beta cell grafts in mice.
    Demine S; Garcia Ribeiro R; Thevenet J; Marselli L; Marchetti P; Pattou F; Kerr-Conte J; Devoogdt N; Eizirik DL
    Diabetologia; 2020 Apr; 63(4):825-836. PubMed ID: 31873789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adipose stem cells from chronic pancreatitis patients improve mouse and human islet survival and function.
    Song L; Sun Z; Kim DS; Gou W; Strange C; Dong H; Cui W; Gilkeson G; Morgan KA; Adams DB; Wang H
    Stem Cell Res Ther; 2017 Aug; 8(1):192. PubMed ID: 28854965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Agonist of growth hormone-releasing hormone as a potential effector for survival and proliferation of pancreatic islets.
    Ludwig B; Ziegler CG; Schally AV; Richter C; Steffen A; Jabs N; Funk RH; Brendel MD; Block NL; Ehrhart-Bornstein M; Bornstein SR
    Proc Natl Acad Sci U S A; 2010 Jul; 107(28):12623-8. PubMed ID: 20616039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the prostaglandin D
    Abadpour S; Tyrberg B; Schive SW; Huldt CW; Gennemark P; Ryberg E; Rydén-Bergsten T; Smith DM; Korsgren O; Skrtic S; Scholz H; Winzell MS
    Diabetologia; 2020 Jul; 63(7):1355-1367. PubMed ID: 32350565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of alogliptin and pioglitazone on lipid metabolism in islets of prediabetic and diabetic Zucker Diabetic Fatty rats.
    Cai Y; Lydic TA; Turkette T; Reid GE; Olson LK
    Biochem Pharmacol; 2015 May; 95(1):46-57. PubMed ID: 25801003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.